Current Report Filing (8-k)
March 14 2018 - 7:23AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 14, 2018
PROTEOSTASIS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-37695
|
|
20-8436652
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
200 Technology Square, 4th Floor
Cambridge, MA 02139
(Address of principal executive offices, including zip code)
(617)
225-0096
(Registrants telephone number, including area code)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 2.02
|
Results of Operations and Financial Condition
|
On March 14, 2018, Proteostasis
Therapeutics, Inc. (the Company) expects to disclose the following information in discussions to be held in connection with the Cowen & Co. Annual Healthcare Conference: As of December 31, 2017, the Company had
approximately $74.5 million in cash, cash equivalents and short-term investments, which the Company estimates to be sufficient to fund operations into early 2019. See additional information in the presentation furnished as an exhibit to Item
7.01.
Item 7.01
|
Regulation FD Disclosure.
|
On March 14, 2018, spokespersons of the Company
presented the information in the slides attached hereto as Exhibit 99.1.
The furnishing of the attached presentation slides is not an
admission as to the materiality of any information therein. The information contained in the presentation slides is summary information that is intended to be considered in the context of more complete information included in the Companys
filings with the U.S. Securities and Exchange Commission, or the SEC, and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or
revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases
or through other public disclosures. For important information about forward looking statements, see the slide titled Safe Harbor and Disclaimer in Exhibit 99.1 attached hereto.
The information in this Item 7.01 of this Current Report on
Form 8-K and
Exhibit 99.1
attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended. The information contained in this Item 7.01 and in the presentation slides attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made
before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: March 14, 2018
|
|
|
|
Proteostasis Therapeutics, Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Meenu Chhabra
|
|
|
|
|
|
|
Meenu Chhabra
|
|
|
|
|
|
|
President and Chief Executive Officer
|
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Sep 2023 to Sep 2024